Article Information
History
- December 1, 2021.
Article Versions
- Version 1 (March 11, 2021 - 18:06).
- Version 2 (March 15, 2021 - 12:54).
- Version 3 (April 20, 2021 - 09:19).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Davide De Forni1,*,
- Barbara Poddesu1,
- Giulia Cugia1,
- Giovanni Gallizia2,
- Massimo La Licata2,
- Julianna Lisziewicz3,
- James Chafouleas1,4 and
- Franco Lori1
- 1ViroStatics s.r.l., Sassari (SS), Italy
- 2M2L s.r.l., Vicenza (VI), Italy
- 3Research Institute for Genetic and Human Therapy, Colorado Springs (CO), USA
- 4Sonnet Pharma Consulting Inc., Quebec, Canada
- ↵* Corresponding author; email: d.deforni{at}virostatics.com
Posted December 01, 2021.
